Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies

Author(s): Michele Moschetta, Marta Cesca, Francesca Pretto, Raffaella Giavazzi

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 35 , 2010

Become EABM
Become Reviewer


Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.

Keywords: Angiogenesis, VEGF, Combination Therapy, Biomarker, Resistance, Toxicity, bevacizumab, Avastin, TKRI, sunitinib, GIST, pazopanib, EGFR, PDGFR, FGFR, CRC, NSCLC, ABT-869, Axitinib, BIBF1120, Brivanib, Cediranib, Dovitinib, Foretinib, Motesanib, Sorafenib, Vandetanib, Vatalanib, ZD6474, carboplatin, paclitaxel, trastuzumab, Radio-Immunotherapy, Tregs, TKRI therapy, PlGF, hypothyroidism, neuropathy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [3921 - 3931]
Pages: 11
DOI: 10.2174/138161210794455021
Price: $65

Article Metrics

PDF: 5